Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn's disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy

Publikováno v: European Journal of Gastroenterology & Hepatology. 35(1):45-51

BACKGROUND: A considerable proportion of Crohn's disease patients that undergo ileocecal resection (ICR) have failed anti-tumor necrosis factor (TNF) therapy preoperatively. This study aimed to assess the effectiveness of retreatment of anti-TNF ther

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od________83::03a4d5043de578b844c2185b0e9e56d4
https://doi.org/10.1097/MEG.0000000000002474

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy

Autor: Stine Sofie Frank Lende, Marie Høst Pahus, Ida Monrad, Rikke Olesen, Anna R. Mahr, Line K. Vibholm, Lars Østergaard, Ole Schmeltz Søgaard, Anna Halling Folkmar Andersen, Paul W. Denton, Martin Tolstrup

Publikováno v: Lende, S S F, Pahus, M H, Monrad, I, Olesen, R, Mahr, A R, Vibholm, L K, Østergaard, L, Søgaard, O S, Andersen, A H F, Denton, P W & Tolstrup, M 2022, ' CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy ', Frontiers in cellular and infection microbiology, vol. 12, 919097 . https://doi.org/10.3389/fcimb.2022.919097

Immunotherapy is a promising therapeutic area in cancer and chronic viral infections. An important component of immunotherapy in these contexts is the activation of innate immunity. Here we investigate the potential for CD169 (Siglec 1) expression on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4bca9bc0cf91f600302bdf004fd0f35
https://doi.org/10.3389/fcimb.2022.919097

Experiences of resuming life after immunotherapy and associated survivorship care needs: A qualitative study among patients with metastatic melanoma

Autor: Nadia C.W. Kamminga, Astrid A.M. van der Veldt, Margot C.W. Joosen, Karlijn de Joode, Arjen Joosse, Dirk J. Grünhagen, Tamar E.C. Nijsten, Marlies Wakkee, Marjolein Lugtenberg

Publikováno v: The British Journal of Dermatology, 187(3), 381-391. Wiley-Blackwell
British Journal of Dermatology, 187(3), 381-391. Wiley-Blackwell Publishing Ltd

Background Immune checkpoint inhibitors (ICIs) have significantly improved the overall survival of patients with metastatic melanoma. It is unclear how the growing group of metastatic melanoma survivors resume their lives after treatment, and which n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf72e770b0493dd87aa020b2eee1cb8
https://research.tilburguniversity.edu/en/publications/69f9498d-5186-4d84-a06d-47efa117608e

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries

Autor: Alexander Egeberg, Nana Aviaaja Lippert Rosenø, David Aagaard, Erik Hillo Lørup, Mia-Louise Nielsen, Lea Nymand, Lars Erik Kristensen, Jacob P. Thyssen, Simon Francis Thomsen, Rene Lindholm Cordtz, Nikolai Loft, Lone Skov, Lars Erik Bryld, Mads Kirchheiner Rasmussen, Pil Højgaard, Salome Kristensen, Lene Dreyer

Publikováno v: Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M-L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979
Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M-L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, pp. 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979
Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979

OBJECTIVE: Drug survival is an important proxy measure for effectiveness of treatments for inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA), and psoriasis. The objective of this study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c027781d394f5dcaf784ece9841db344
https://pubmed.ncbi.nlm.nih.gov/35183936

Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis

Autor: Miguel D'haeseleer, Famke Vanderhauwaert, Jens Devogelaere, Marie B. D'hooghe

Publikováno v: Neurological Sciences

The rapid and global spread of severe acute respiratory syndrome coronavirus 2, a viral pathogen responsible for the development of the "coronavirus disease of 2019" (COVID-19), has developed into an unprecedented health crisis with considerable case

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d962a9da7291357f7e94a0d7309e53fa
https://doi.org/10.1007/s10072-020-04522-2